- Home
- CHRS vs ASRT Comparison
CHRS vs ASRT Comparison
Compare CHRS & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- ASRT
- Stock Information
- Founded
- CHRS 2010
- ASRT 1995
- Country
- CHRS United States
- ASRT United States
- Employees
- CHRS N/A
- ASRT N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- ASRT Health Care
- Exchange
- CHRS Nasdaq
- ASRT Nasdaq
- Market Cap
- CHRS 94.0M
- ASRT 78.3M
- IPO Year
- CHRS 2014
- ASRT 1997
- Fundamental
- Price
- CHRS $0.91
- ASRT $0.67
- Analyst Decision
- CHRS Strong Buy
- ASRT Strong Buy
- Analyst Count
- CHRS 4
- ASRT 3
- Target Price
- CHRS $5.38
- ASRT $3.08
- AVG Volume (30 Days)
- CHRS 2.1M
- ASRT 412.7K
- Earning Date
- CHRS 05-08-2025
- ASRT 05-05-2025
- Dividend Yield
- CHRS N/A
- ASRT N/A
- EPS Growth
- CHRS N/A
- ASRT N/A
- EPS
- CHRS 0.25
- ASRT N/A
- Revenue
- CHRS $266,959,999.00
- ASRT $124,961,000.00
- Revenue This Year
- CHRS N/A
- ASRT N/A
- Revenue Next Year
- CHRS $9.02
- ASRT $11.20
- P/E Ratio
- CHRS $3.66
- ASRT N/A
- Revenue Growth
- CHRS 3.78
- ASRT N/A
- 52 Week Low
- CHRS $0.66
- ASRT $0.65
- 52 Week High
- CHRS $2.61
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- CHRS 45.16
- ASRT 35.44
- Support Level
- CHRS $0.89
- ASRT $0.70
- Resistance Level
- CHRS $1.07
- ASRT $0.80
- Average True Range (ATR)
- CHRS 0.09
- ASRT 0.05
- MACD
- CHRS -0.00
- ASRT -0.00
- Stochastic Oscillator
- CHRS 44.79
- ASRT 15.22
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.